New Data, Same Access Challenges for Heart Patients
The risk of death may be lower for certain patients taking cholesterol-lowering PCSK9 inhibitors, new research shows. But how many patients will actually be able to realize the drugs’ benefits? Research Results The latest research found that patients had a significantly lower risk of major cardiovascular events when taking PCSK9 inhibitors. Announced at this weekend’s […]
IfPA Report Cards: 1 in 4 Heart Patients Can’t Access Innovative Rx
Health plans said “no” to one in every four Americans whose doctor prescribed a cholesterol-lowering PCSK9 inhibitor in 2017. And that, according to the Institute for Patient Access’ new access report cards, means that more than 78,000 heart patients went without medicine that could have reduced their risk of heart attack and stroke. National Report […]
Working Group Airs Concerns about Access to Diabetes Care
There was a lot of head nodding at the inaugural meeting of the Alliance for Patient Access’ Diabetes Therapy Access Working Group. Especially when the topic turned to non-medical switching. “Patients get flipped between insulins,” explained Children with Diabetes President Jeff Hitchcock, “and, as often as not, the one that works for them ends up […]
Europeans Work to Turn Health Care Rights into Realities
by Brian Kennedy, Executive Director, Alliance for Patient Access Declaring equal rights is a noble gesture. But history teaches us that it is just the first step in a complex, years-long process – actually establishing and protecting those rights. I was reminded of this reality just recently, when I spoke at a meeting of the European […]
Balancing Opioid Policy and Pain Management
Thursday marked the White House Opioid Summit, which welcomed 200 affected Americans to discuss the crisis with Cabinet members. President Donald Trump declared the opioid abuse epidemic a public health emergency last fall.
PCSK9 Inhibitors: National
A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2017 through December 2017. Of national health plans that received at least 2,000 claims for PCSK9 inhibitors, the following had the highest rates of rejection: • Federal Employee Benefit Plan – […]
PCSK9 Inhibitors: Alabama
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Alabama from January 2017 through December 2017. Of health plans that received at least 100 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • BCBS Alabama – 48% • CVS Health – 45% • Express Scripts – 37% […]
PCSK9 Inhibitors: California
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in California from January 2017 through December 2017. Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • BS of CA – 60% • Express Scripts – 48% • Centene – 46% […]
PCSK9 Inhibitors: Florida
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Florida from January 2017 through December 2017. Of health plans that received at least 300 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • Federal Employee Benefit Plan – 84% • Florida Blue – 51% • Tricare Military […]
PCSK9 Inhibitors: Texas
A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Texas from January 2017 through December 2017. Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had the highest rates of rejections: • Federal Employee Benefit Plan – 82% • Tricare Military Health SVC SYS – 44% […]
